1. Home
  2. Analysis
  3. Januvia
  4. Tymlos

Januvia and Tymlos drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Januvia (sitagliptin phosphate) and Tymlos (abaloparatide). Common drug interactions include headache among females.

The phase IV clinical study analyzes what interactions people have when they take Januvia and Tymlos. It is created by eHealthMe based on reports of 22 people who take the same drugs from the FDA, and is updated regularly.

What is Januvia?

Januvia has active ingredients of sitagliptin phosphate. It is often used in diabetes. eHealthMe is studying from 72,818 Januvia users. Check the latest studies of Januvia.

What is Tymlos?

Tymlos has active ingredients of abaloparatide. eHealthMe is studying from 16,516 Tymlos users. Check the latest studies of Tymlos.

On Aug, 10, 2026

22 people who take Januvia and Tymlos together, and have interactions are studied.

Januvia and Tymlos drug interactions.

What are the common drug interactions of Januvia and Tymlos, by gender? *:

female:

  1. Headache (pain in head)
  2. Fatigue (feeling of tiredness)
  3. Chills (felling of cold)
  4. Decreased appetite
  5. Dizziness postural
  6. Heart rate increased
  7. Malaise (a feeling of general discomfort or uneasiness)
  8. Pain
  9. Sleep disorder
  10. Abdominal discomfort

male:

n/a

What are the common drug interactions of Januvia and Tymlos, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

  1. Thyroid cancer

60+:

  1. Headache (pain in head)
  2. Blood glucose increased
  3. Osteoporosis (bones weak and more likely to break)
  4. Pain in jaw
  5. Pulmonary thrombosis (scarring in the lungs)
  6. Scoliosis (a medical condition in which a person's spine is curved from side to side)
  7. Visual impairment
  8. White blood cell disorder
  9. Anaphylactic reaction (serious allergic reaction)
  10. Bone pain

What are the existing conditions these people have? *

  1. Senile Osteoporosis (weak bones with ageing): 9 people, 40.91%
  2. Osteoporosis Post-Menopausal (weak bone with possibility to break after stopped menstrual cycles): 5 people, 22.73%
  3. Pseudomonas Infection (pseudomonas infection is caused by a bacterium, pseudomonas aeruginosa): 3 people, 13.64%
  4. Osteoporosis (bones weak and more likely to break): 3 people, 13.64%
  5. Osteoporotic Fracture (fracture due to weak bone): 2 people, 9.09%
  6. Adrenocortical Insufficiency Acute (suddenly adrenal glands do not produce adequate amounts of steroid hormones): 2 people, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Januvia and Tymlos?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Januvia and Tymlos:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Januvia:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Tymlos:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Januvia and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Tymlos and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on sitagliptin phosphate and abaloparatide (the active ingredients of Januvia and Tymlos, respectively), and Januvia and Tymlos (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.